PerC B cells in mice that received CsA treatment
| Groups . | No. . | Cells/mouse, × 106 . | Lymphocytes, % total cells . | B cells, % lymphocytes . | B-1a cells, % B cells . | B-1b cells, % B cells . | B-2 cells, % B cells . |
|---|---|---|---|---|---|---|---|
| Control | 5 | 10.8 ± 1.1 | 89.7 ± 1.6 | 83.8 ± 3.7 | 64.0 ± 4.4 | 16.7 ± 2.1 | 15.7 ± 3.4 |
| 5 mg/kg | 3 | 14.5 ± 5.0 | 69.2 ± 0.7 | 61.8 ± 0.8 | 33.7 ± 1.1 | 12.6 ± 0.6 | 47.5 ± 5.9 |
| 10 mg/kg | 5 | 15.7 ± 2.4 | 68.6 ± 2.0 | 66.4 ± 4.3 | 19.6 ± 2.2 | 13.6 ± 2.9 | 66.9 ± 3.8 |
| 50 mg/kg | 5 | 14.3 ± 3.0 | 53.9 ± 9.1 | 57.3 ± 6.9 | 22.3 ± 3.5 | 13.7 ± 1.6 | 61.3 ± 3.9 |
| Groups . | No. . | Cells/mouse, × 106 . | Lymphocytes, % total cells . | B cells, % lymphocytes . | B-1a cells, % B cells . | B-1b cells, % B cells . | B-2 cells, % B cells . |
|---|---|---|---|---|---|---|---|
| Control | 5 | 10.8 ± 1.1 | 89.7 ± 1.6 | 83.8 ± 3.7 | 64.0 ± 4.4 | 16.7 ± 2.1 | 15.7 ± 3.4 |
| 5 mg/kg | 3 | 14.5 ± 5.0 | 69.2 ± 0.7 | 61.8 ± 0.8 | 33.7 ± 1.1 | 12.6 ± 0.6 | 47.5 ± 5.9 |
| 10 mg/kg | 5 | 15.7 ± 2.4 | 68.6 ± 2.0 | 66.4 ± 4.3 | 19.6 ± 2.2 | 13.6 ± 2.9 | 66.9 ± 3.8 |
| 50 mg/kg | 5 | 14.3 ± 3.0 | 53.9 ± 9.1 | 57.3 ± 6.9 | 22.3 ± 3.5 | 13.7 ± 1.6 | 61.3 ± 3.9 |
CD5+ B-1a cells exclusively decreased, but CD5− B-2 increased in the PerC of the mice treated with CsA. After 2 weeks daily intraperitoneal injection of various doses of CsA into Balb/c mice, peritoneal cavity cells were harvested and stained with mAbs against B220 (RA3-6B2), CD11b (M1/70), and CD5 (53-7.3) to determine B-cell subsets (B-1a, B220+CD11b+CD5+, B-1b, B220+CD11b+CD5−, B-2, and B220+CD11b−CD5−. B-1a cells have been well defined as CD19+ B220+ sIgM+ CD11b+ CD5+ cells. Since B220+ CD11b+ CD5+ cells universally expressed both sIgM and CD19, and sIgM+ CD11b+ CD5+ cells universally expressed both CD19 and B220 in our previous studies, we considered both B220+ CD11b+ CD5+ cells and sIgM+ CD11b+ CD5+ cells as B-1a cells. All mAbs were purchased from BD PharMingen). Mean percentages (± SEM) are shown.